Single-use Bioprocessing Market - Global Outlook & Forecast 2023-2028

Description

The global single-use bioprocessing market is expected to grow at a CAGR of 19.74% from 2022 to 2028.

MARKET TRENDS & DRIVERS

New Product Launches

Technological advances have been key in introducing new single-use bioprocess consumables worldwide. Players in the single-use bioprocessing market have launched new products that make single-use bioprocessing safer, easier, and more efficient than ever before. Such factors have allowed companies to gain market share by meeting market demands. Market participants apply for patents on single-use disposable bioprocessing products that protect novel designs. The increasing availability of single-use technology for production applications and the launch of new products creates an environment where companies can quickly and easily adopt the technology and begin reaping the benefits. Companies can now reduce costs and improve efficiency in their production processes by replacing traditional, labor-intensive methods with single-use technology.

Increasing Strategic Acquisitions and Collaborations

The strategic acquisition of single-use technology can enhance adoption across biopharmaceuticals. Single-use technology is a cost-effective and efficient way to streamline operations, reduce waste, and improve quality control. By strategically acquiring high-quality single-use technology, organizations can increase their competitive advantage while reducing costs and increasing efficiency. The strategic acquisition of single-use technology can increase the visibility and control of processes, resulting in increased transparency and compliance with industry regulations. The strategic acquisition of single-use technology can be a powerful tool for organizations looking to reduce costs, increase efficiency, and improve their competitive advantage. In addition, the industry players are adopting partnership strategies to facilitate access to local single-use bioprocessing markets.

Growing Biomanufacturing Capacity and Uptake of Biopharmaceuticals & Biosimilars

The growing biomanufacturing capacity and uptake of biopharmaceuticals and biosimilars drive the single-use bioprocessing market. Single-use bioprocessing provides a valuable platform for producing biopharmaceuticals, biotherapeutics, vaccines, monoclonal antibodies, and biosimilars. With advances in biomanufacturing, single-use bioprocessing offers greater flexibility, shorter process times, improved scalability, lower capital costs, and reduced product contamination risks. Additionally, single-use bioprocessing eliminates the need for extensive cleaning and sterilization of equipment, thus reducing operational costs.

SEGMENTATION INSIGHTS

INSIGHTS BY PRODUCT TYPE

Single-use bioprocessing equipment is a technology that has revolutionized the biopharmaceutical industry. This technology has increased efficiency, flexibility, safety, and cost savings during bioprocessing. Single-use bioprocessing equipment is a system of technologies designed to replace reusable stainless steel and other materials traditionally used in bioprocessing. This equipment uses single-use components, including bags, bioreactors, tubing, syringes, connectors, and filters, disposed of after use. In 2022, the single-use bioprocessing equipment product type held a larger share of the global single-use bioprocessing market.

Segmentation by Product Type

Single-use Bioprocessing Equipment
Simple & Peripheral Devices

INSIGHTS BY APPLICATION

The global single-use bioprocessing market by application is segmented as monoclonal antibodies (mABs), vaccines, cell therapies, and others. Monoclonal antibodies (mABs) hold the largest industry share by application segment. Single-use bioprocessing is an emerging technology in the biopharmaceutical industry that has revolutionized how monoclonal antibodies (mAbs) are produced. Single-use bioprocessing involves using disposable bioreactors and other components to produce proteins, such as mAbs. Unlike traditional stainless-steel bioreactors, single-use bioreactors can be quickly set up, require minimal cleaning, and reduce the risk of cross-contamination. Due to their complexity and high cost, these advantages make single-use bioprocessing particularly attractive for mAb production.

Segmentation by Application

Monoclonal Antibodies (mABs)
Vaccines
Cell Therapies
Others

INSIGHTS BY END-USER

The biopharmaceutical manufacturers segment accounted for over 39% of the global single-use bioprocessing market. This segment dominates the overall market and will likely retain its dominance in the coming years due to its widespread adoption in research and commercial manufacturing applications. Several biopharmaceutical manufacturers have already explored SUB solutions usage in commercial manufacturing. However, their potential benefits are significant, particularly in small-volume manufacturing in modular facilities. Most biopharmaceutical manufacturers, especially large and medium-sized companies, spend over $50 million on equipment annually. It has been witnessed that a high percentage of capital is being spent on single-use bioprocessing by biopharmaceutical manufacturers.

Segmentation by End-users

Biopharmaceutical Manufacturers
Contract Manufacturing Organizations (CMOs)
R&D Companies & Research Institutes

INSIGHTS BY METHOD

The global single-use bioprocessing market by the method is categorized as filtration, storage & transport, cell culture, mixing, and purification. Filtration holds the largest share of the market. Single-use bioprocessing is a method of filtration that has grown increasingly popular in the biotechnology industry. It involves using disposable, self-contained systems to prepare, filter, and process bioproducts. This form of filtration has many advantages, especially for pharmaceutical and biological product manufacturing. Single-use bioprocessing has revolutionized the biotechnology industry. This reduces the need for traditional equipment and infrastructure, resulting in cost savings and improved production efficiency.

Segmentation by Method

Filtration
Storage & Transport
Cell Culture
Mixing
Purification

INSIGHTS BY WORKFLOW

The upstream workflow segment dominated the global single-use bioprocessing market. Upstream single-use bioprocessing workflow is focused on upstream unit operations such as cell culture, protein expression, and harvest. Over the last decade, advances in this workflow have enabled biopharmaceutical companies to streamline the process, increase product yields, and reduce costs. The upstream single-use bioprocessing workflow advancements have provided biopharmaceutical companies with a more efficient and cost-effective workflow.

Segmentation by Workflow

Upstream
Downstream

GEOGRAPHICAL ANALYSIS

The single-use bioprocessing market in North America is growing significantly and is expected to grow at a similar pace during the forecast period. Increasing demand for biologics from patients, especially the elderly, high investments in R&D activities by biopharmaceutical companies, and patent expiries of biologics are the key drivers for the single-use bioprocessing market in North America. North America, especially the U.S., is known for its in-house biopharmaceutical manufacturing facilities, which have bolstered the adoption of disposables (simple and peripheral devices) and highly advanced single-use systems such as mixing systems, bioreactors, and cell culture systems over the past few years.

Segmentation by Geography

North America
- The U.S.
- Canada
Europe
- Germany
- France
- Switzerland
- The U.K.
- Italy
- Spain
APAC
- China
- Japan
- Australia
- South Korea
- India
Latin America
- Brazil
- Mexico
- Colombia
- Argentina
Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- South Africa

VENDOR LANDSCAPE

The global single-use bioprocessing market is highly dynamic and offers significant growth opportunities for vendors. Although the industry is characterized by the presence of several global as well as local players, a few major global players hold significant shares, offering a broad range of SUTs. As the market offers tremendous growth opportunities, new players are expected to enter, intensifying the competition. Rising competition among SUT manufacturers is expected to drive significant product development, such as providing single-use bioreactors with large manufacturing volumes and capacities.

Key Company Profiles

Thermo Fisher Scientific
Sartorius Stedim Biotech
Danaher
Merck KGaA
Avantor

Other Prominent Vendors

3i Group
3M
ABEC
Adolf Kuhner
AdvantaPure
Barry-Wehmiller Companies
Broadley-James
Celltainer Biotech
CerCell A/S
CESCO Bioengineering
Charter Medical
Colder Products Company
Corning
Distek
DrM, Dr. Mueller
Emerson Electric
Entegris
Eppendorf
Foxx Life Sciences
Getinge
HIGH PURITY NEW ENGLAND
Holland Applied Technologies
Lonza
MEISSNER FILTRATION PRODUCTS
New Horizon Biotech
OmniBRx Biotechnologies
PARKER HANNIFIN
PendoTECH
PBS Biotech
Repligen
Saint-Gobain
Sentinel Process Systems
Solaris Biotechnology
SYSBIOTECH GmbH
Watson-Marlow Fluid Technology Solutions
Weigao Group
W.L. Gore & Associates

KEY QUESTIONS ANSWERED:

1. How big is the global single-use bioprocessing market?
2. What is the growth rate of the single-use bioprocessing market?
3. What are the rising trends in the single-use bioprocessing market?
4. Which region holds the most significant global single-use bioprocessing market share?
5. Who are the key players in the global single-use bioprocessing market?

Product Code: ARZ230614

1 RESEARCH METHODOLOGY

2 RESEARCH OBJECTIVES

3 RESEARCH PROCESS

4 SCOPE & COVERAGE

4.1 MARKET DEFINITION
- 4.1.1 INCLUSIONS
- 4.1.2 EXCLUSIONS
- 4.1.3 MARKET ESTIMATION CAVEATS
4.2 BASE YEAR
4.3 SCOPE OF THE STUDY
- 4.3.1 MARKET SEGMENTATION BY PRODUCT
- 4.3.2 MARKET SEGMENTATION BY APPLICATION
- 4.3.3 MARKET SEGMENTATION BY END-USERS
- 4.3.4 MARKET SEGMENTATION BY METHOD
- 4.3.5 MARKET SEGMENTATION BY WORKFLOW
- 4.3.6 MARKET SEGMENTATION BY GEOGRAPHY

5 REPORT ASSUMPTIONS & CAVEATS

5.1 KEY CAVEATS
5.2 CURRENCY CONVERSION
5.3 MARKET DERIVATION

6 PREMIUM INSIGHTS

6.1 MARKET OVERVIEW
- 6.1.1 GEOGRAPHY INSIGHTS
- 6.1.2 PRODUCT TYPE INSIGHTS
- 6.1.3 APPLICATION INSIGHTS
- 6.1.4 END-USER INSIGHTS
- 6.1.5 METHOD INSIGHTS
- 6.1.6 WORKFLOW INSIGHTS

7 MARKET AT A GLANCE

8 INTRODUCTION

8.1 OVERVIEW

9 MARKET OPPORTUNITIES & TRENDS

9.1 SINGLE-USE TECHNOLOGY IN CELL AND GENE THERAPY
9.2 INCREASING DEMAND FOR CONTINUOUS BIOPROCESSING
9.3 TECHNOLOGICAL ADVANCES IN SINGLE-USE BIOPROCESSING (SUB)
9.4 NEW PRODUCT LAUNCHES
9.5 INCREASING STRATEGIC ACQUISITIONS AND COLLABORATIONS

10 MARKET GROWTH ENABLERS

10.1 GROWING BIOMANUFACTURING CAPACITY AND UPTAKE OF BIOPHARMACEUTICALS & BIOSIMILARS
10.2 LOWER CAPITAL INVESTMENT IN SUTS OVER MULTI-USE PLATFORMS AND LESS FLOOR SPACE REQUIREMENTS
10.3 INCREASED ACCEPTANCE OF SUS TO ENHANCE BIOMANUFACTURING PRODUCTIVITY AND EFFICIENCY
10.4 REDUCED WATER CONSUMPTION AND LESSER ENVIRONMENTAL IMPACT OF SINGLE-USE TECHNOLOGIES

11 MARKET RESTRAINTS

11.1 THE CHANGING SCALE OF SINGLE-USE OPERATIONS
11.2 LOW STRENGTH OF SUPPLY CHAIN AND LACK OF STANDARDIZATION
11.3 ISSUES RELATED TO LEACHABLES AND EXTRACTABLES

12 MARKET LANDSCAPE

12.1 MARKET OVERVIEW
12.2 MARKET SIZE & FORECAST
12.3 MARKET OPPORTUNITY
- 12.3.1 MARKET BY PRODUCT
- 12.3.2 MARKET BY APPLICATION
- 12.3.3 MARKET BY END-USER
- 12.3.4 MARKET BY METHOD
- 12.3.5 MARKET BY WORKFLOW
- 12.3.6 MARKET BY GEOGRAPHY
12.4 FIVE FORCES ANALYSIS
- 12.4.1 THREAT OF NEW ENTRANTS
- 12.4.2 BARGAINING POWER OF SUPPLIERS
- 12.4.3 BARGAINING POWER OF BUYERS
- 12.4.4 THREAT OF SUBSTITUTES
- 12.4.5 COMPETITIVE RIVALRY

13 PRODUCT TYPE

13.1 MARKET SNAPSHOT & GROWTH ENGINE
13.2 MARKET OVERVIEW
13.3 SINGLE-USE BIOPROCESSING EQUIPMENT
- 13.3.1 MARKET OVERVIEW
- 13.3.2 MARKET SIZE & FORECAST
- 13.3.3 SINGLE-USE BIOPROCESSING EQUIPMENT MARKET BY GEOGRAPHY
13.4 SIMPLE & PERIPHERAL DEVICES
- 13.4.1 MARKET OVERVIEW
- 13.4.2 MARKET SIZE & FORECAST
- 13.4.3 SIMPLE & PERIPHERAL DEVICES MARKET BY GEOGRAPHY

14 APPLICATION

14.1 MARKET SNAPSHOT & GROWTH ENGINE
14.2 MARKET OVERVIEW
14.3 MONOCLONAL ANTIBODIES
- 14.3.1 MARKET OVERVIEW
- 14.3.2 MARKET SIZE & FORECAST
- 14.3.3 MONOCLONAL ANTIBODIES (MABS) MARKET BY GEOGRAPHY
14.4 VACCINES
- 14.4.1 MARKET OVERVIEW
- 14.4.2 MARKET SIZE & FORECAST
- 14.4.3 VACCINES MARKET BY GEOGRAPHY
14.5 CELL THERAPIES
- 14.5.1 MARKET OVERVIEW
- 14.5.2 MARKET SIZE & FORECAST
- 14.5.3 CELL THERAPIES MARKET BY GEOGRAPHY
14.6 OTHERS
- 14.6.1 MARKET OVERVIEW
- 14.6.2 MARKET SIZE & FORECAST
- 14.6.3 OTHERS MARKET BY GEOGRAPHY

15 END-USER

15.1 MARKET SNAPSHOT & GROWTH ENGINE
15.2 MARKET OVERVIEW
15.3 BIOPHARMACEUTICAL MANUFACTURERS
- 15.3.1 MARKET OVERVIEW
- 15.3.2 MARKET SIZE & FORECAST
- 15.3.3 BIOPHARMACEUTICAL MANUFACTURERS MARKET BY GEOGRAPHY
15.4 CONTRACT MANUFACTURING ORGANIZATIONS (CMO)
- 15.4.1 MARKET OVERVIEW
- 15.4.2 MARKET SIZE & FORECAST
- 15.4.3 CONTRACT MANUFACTURING ORGANIZATIONS (CMOS) MARKET BY GEOGRAPHY
15.5 R&D COMPANIES AND RESEARCH INSTITUTES
- 15.5.1 MARKET OVERVIEW
- 15.5.2 MARKET SIZE & FORECAST
- 15.5.3 R&D COMPANIES AND RESEARCH INSTITUTES MARKET BY GEOGRAPHY

16 METHOD

16.1 MARKET SNAPSHOT & GROWTH ENGINE
16.2 MARKET OVERVIEW
16.3 FILTRATION
- 16.3.1 MARKET OVERVIEW
- 16.3.2 MARKET SIZE & FORECAST
16.4 STORAGE & TRANSPORT
- 16.4.1 MARKET OVERVIEW
- 16.4.2 MARKET SIZE & FORECAST
16.5 CELL CULTURE
- 16.5.1 MARKET OVERVIEW
- 16.5.2 MARKET SIZE & FORECAST
16.6 MIXING
- 16.6.1 MARKET OVERVIEW
- 16.6.2 MARKET SIZE & FORECAST
16.7 PURIFICATION
- 16.7.1 MARKET OVERVIEW
- 16.7.2 MARKET SIZE & FORECAST

17 WORKFLOW

17.1 MARKET SNAPSHOT & GROWTH ENGINE
17.2 MARKET OVERVIEW
17.3 UPSTREAM
- 17.3.1 MARKET OVERVIEW
- 17.3.2 MARKET SIZE & FORECAST
17.4 DOWNSTREAM
- 17.4.1 MARKET OVERVIEW
- 17.4.2 MARKET SIZE & FORECAST

18 GEOGRAPHY

18.1 MARKET SNAPSHOT & GROWTH ENGINE
18.2 GEOGRAPHIC OVERVIEW

19 NORTH AMERICA

19.1 MARKET OVERVIEW
19.2 MARKET SIZE & FORECAST
- 19.2.1 NORTH AMERICA MARKET BY PRODUCT TYPE
- 19.2.2 NORTH AMERICA MARKET BY APPLICATION
- 19.2.3 NORTH AMERICA MARKET BY END-USER
19.3 KEY COUNTRIES
- 19.3.1 US: MARKET SIZE & FORECAST
- 19.3.2 CANADA: MARKET SIZE & FORECAST

20 EUROPE

20.1 MARKET OVERVIEW
20.2 MARKET SIZE & FORECAST
- 20.2.1 EUROPE MARKET BY PRODUCT TYPE
- 20.2.2 EUROPE MARKET BY APPLICATION
- 20.2.3 EUROPE MARKET BY END-USER
20.3 KEY COUNTRIES
- 20.3.1 GERMANY: MARKET SIZE & FORECAST
- 20.3.2 FRANCE: MARKET SIZE & FORECAST
- 20.3.3 SWITZERLAND: MARKET SIZE & FORECAST
- 20.3.4 UK: MARKET SIZE & FORECAST
- 20.3.5 ITALY: MARKET SIZE & FORECAST
- 20.3.6 SPAIN: MARKET SIZE & FORECAST

21 APAC

21.1 MARKET OVERVIEW
21.2 MARKET SIZE & FORECAST
- 21.2.1 APAC MARKET BY PRODUCT TYPE
- 21.2.2 APAC MARKET BY APPLICATION
- 21.2.3 APAC MARKET BY END-USER
21.3 KEY COUNTRIES
- 21.3.1 CHINA: MARKET SIZE & FORECAST
- 21.3.2 JAPAN: MARKET SIZE & FORECAST
- 21.3.3 AUSTRALIA: MARKET SIZE & FORECAST
- 21.3.4 SOUTH KOREA: MARKET SIZE & FORECAST
- 21.3.5 INDIA: MARKET SIZE & FORECAST

22 LATIN AMERICA

22.1 MARKET OVERVIEW
22.2 MARKET SIZE & FORECAST
- 22.2.1 LATIN AMERICA MARKET BY PRODUCT TYPE
- 22.2.2 LATIN AMERICA MARKET BY APPLICATION
- 22.2.3 LATIN AMERICA MARKET BY END-USER
22.3 KEY COUNTRIES
- 22.3.1 BRAZIL: MARKET SIZE & FORECAST
- 22.3.2 MEXICO: MARKET SIZE & FORECAST
- 22.3.3 COLOMBIA: MARKET SIZE & FORECAST
- 22.3.4 ARGENTINA: MARKET SIZE & FORECAST

23 MIDDLE EAST & AFRICA

23.1 MARKET OVERVIEW
23.2 MARKET SIZE & FORECAST
- 23.2.1 MIDDLE EAST & AFRICA MARKET BY PRODUCT TYPE
- 23.2.2 MIDDLE EAST & AFRICA MARKET BY APPLICATION
- 23.2.3 MIDDLE EAST & AFRICA MARKET BY END-USER
23.3 KEY COUNTRIES
- 23.3.1 TURKEY: MARKET SIZE & FORECAST
- 23.3.2 SAUDI ARABIA: MARKET SIZE & FORECAST
- 23.3.3 UAE: MARKET SIZE & FORECAST
- 23.3.4 SOUTH AFRICA: MARKET SIZE & FORECAST

24 COMPETITIVE LANDSCAPE

24.1 COMPETITION OVERVIEW
- 24.1.1 VENDOR ACTIVITIES IN SINGLE-USE BIOPROCESSING MARKET
24.2 MARKET SHARE ANALYSIS
- 24.2.1 THERMO FISHER SCIENTIFIC
- 24.2.2 SARTORIUS STEDIM BIOTECH
- 24.2.3 DANAHER
- 24.2.4 MERCK KGAA
- 24.2.5 AVANTOR

25 KEY COMPANY PROFILES

25.1 THERMO FISHER SCIENTIFIC
- 25.1.1 BUSINESS OVERVIEW
- 25.1.2 PRODUCT OFFERINGS
- 25.1.3 KEY STRATEGIES
- 25.1.4 KEY STRENGTHS
- 25.1.5 KEY OPPORTUNITIES
25.2 SARTORIUS STEDIM BIOTECH
- 25.2.1 BUSINESS OVERVIEW
- 25.2.2 PRODUCT OFFERINGS
- 25.2.3 KEY STRATEGIES
- 25.2.4 KEY STRENGTHS
- 25.2.5 KEY OPPORTUNITIES
25.3 DANAHER
- 25.3.1 BUSINESS OVERVIEW
- 25.3.2 PRODUCT OFFERINGS
- 25.3.3 KEY STRATEGIES
- 25.3.4 KEY STRENGTHS
- 25.3.5 KEY OPPORTUNITIES
25.4 MERCK KGAA
- 25.4.1 BUSINESS OVERVIEW
- 25.4.2 PRODUCT OFFERINGS
- 25.4.3 KEY STRATEGIES
- 25.4.4 KEY STRENGTHS
- 25.4.5 KEY OPPORTUNITIES
25.5 AVANTOR
- 25.5.1 BUSINESS OVERVIEW
- 25.5.2 PRODUCT OFFERINGS
- 25.5.3 KEY STRATEGIES
- 25.5.4 KEY STRENGTHS
- 25.5.5 KEY OPPORTUNITIES

26 OTHER PROMINENT VENDORS

26.1 3I GROUP
- 26.1.1 BUSINESS OVERVIEW
- 26.1.2 PRODUCT OFFERINGS
26.2 3M
- 26.2.1 BUSINESS OVERVIEW
- 26.2.2 PRODUCT OFFERINGS
26.3 ABEC
- 26.3.1 BUSINESS OVERVIEW
- 26.3.2 PRODUCT OFFERINGS
26.4 ADOLF KUHNER
- 26.4.1 BUSINESS OVERVIEW
- 26.4.2 PRODUCT OFFERINGS
26.5 ADVANTAPURE
- 26.5.1 BUSINESS OVERVIEW
- 26.5.2 PRODUCT OFFERINGS
26.6 BARRY-WEHMILLER COMPANIES
- 26.6.1 BUSINESS OVERVIEW
- 26.6.2 PRODUCT OFFERING
26.7 BROADLEY-JAMES
- 26.7.1 BUSINESS OVERVIEW
- 26.7.2 PRODUCT OFFERINGS
26.8 CELLTAINER BIOTECH
- 26.8.1 BUSINESS OVERVIEW
- 26.8.2 PRODUCT OFFERINGS
26.9 CERCELL A/S
- 26.9.1 BUSINESS OVERVIEW
- 26.9.2 PRODUCT OFFERINGS
26.10 CESCO BIOENGINEERING
- 26.10.1 BUSINESS OVERVIEW
- 26.10.2 PRODUCT OFFERINGS
26.11 CHARTER MEDICAL
- 26.11.1 BUSINESS OVERVIEW
- 26.11.2 PRODUCT OFFERINGS
26.12 COLDER PRODUCTS COMPANY
- 26.12.1 BUSINESS OVERVIEW
- 26.12.2 PRODUCT OFFERINGS
26.13 CORNING
- 26.13.1 BUSINESS OVERVIEW
- 26.13.2 PRODUCT OFFERINGS
26.14 DISTEK
- 26.14.1 BUSINESS OVERVIEW
- 26.14.2 PRODUCT OFFERINGS
26.15 DRM, DR. MUELLER
- 26.15.1 BUSINESS OVERVIEW
- 26.15.2 PRODUCT OFFERINGS
26.16 EMERSON ELECTRIC
- 26.16.1 BUSINESS OVERVIEW
- 26.16.2 PRODUCT OFFERINGS
26.17 ENTEGRIS
- 26.17.1 BUSINESS OVERVIEW
- 26.17.2 PRODUCT OFFERINGS
26.18 EPPENDORF
- 26.18.1 BUSINESS OVERVIEW
- 26.18.2 PRODUCT OFFERINGS
26.19 FOXX LIFE SCIENCES
- 26.19.1 BUSINESS OVERVIEW
- 26.19.2 PRODUCT OFFERINGS
26.20 GETINGE
- 26.20.1 BUSINESS OVERVIEW
- 26.20.2 PRODUCT OFFERINGS
26.21 HIGH-PURITY NEW ENGLAND
- 26.21.1 BUSINESS OVERVIEW
- 26.21.2 PRODUCT OFFERINGS
26.22 HOLLAND APPLIED TECHNOLOGIES
- 26.22.1 BUSINESS OVERVIEW
- 26.22.2 PRODUCT OFFERINGS
26.23 LONZA
- 26.23.1 BUSINESS OVERVIEW
- 26.23.2 PRODUCT OFFERINGS
26.24 MEISSNER FILTRATION PRODUCTS
- 26.24.1 BUSINESS OVERVIEW
- 26.24.2 PRODUCT OFFERINGS
26.25 NEW HORIZON BIOTECH
- 26.25.1 BUSINESS OVERVIEW
- 26.25.2 PRODUCT OFFERINGS
26.26 OMNIBRX BIOTECHNOLOGIES
- 26.26.1 BUSINESS OVERVIEW
- 26.26.2 PRODUCT OFFERINGS
26.27 PARKER HANNIFIN
- 26.27.1 BUSINESS OVERVIEW
- 26.27.2 PRODUCT OFFERINGS
26.28 PENDOTECH
- 26.28.1 BUSINESS OVERVIEW
- 26.28.2 PRODUCT OFFERINGS
26.29 PBS BIOTECH
- 26.29.1 BUSINESS OVERVIEW
- 26.29.2 PRODUCT OFFERINGS
26.30 REPLIGEN
- 26.30.1 BUSINESS OVERVIEW
- 26.30.2 PRODUCT OFFERINGS
26.31 SAINT-GOBAIN
- 26.31.1 BUSINESS OVERVIEW
- 26.31.2 PRODUCT OFFERINGS
26.32 SENTINEL PROCESS SYSTEMS
- 26.32.1 BUSINESS OVERVIEW
- 26.32.2 PRODUCT OFFERINGS
26.33 SOLARIS BIOTECHNOLOGY
- 26.33.1 BUSINESS OVERVIEW
- 26.33.2 PRODUCT OFFERINGS
26.34 SYSBIOTECH
- 26.34.1 BUSINESS OVERVIEW
- 26.34.2 PRODUCT OFFERINGS
26.35 WATSON-MARLOW FLUID TECHNOLOGY SOLUTIONS
- 26.35.1 BUSINESS OVERVIEW
- 26.35.2 PRODUCT OFFERINGS
26.36 WEIGAO GROUP
- 26.36.1 BUSINESS OVERVIEW
- 26.36.2 PRODUCT OFFERINGS
26.37 W.L. GORE & ASSOCIATES
- 26.37.1 BUSINESS OVERVIEW
- 26.37.2 PRODUCT OFFERINGS

27 REPORT SUMMARY

27.1 KEY TAKEAWAYS
27.2 STRATEGIC RECOMMENDATIONS

28 QUANTITATIVE SUMMARY

28.1 MARKET BY PRODUCT TYPE
- 28.1.1 NORTH AMERICA MARKET BY PRODUCT TYPE
- 28.1.2 EUROPE MARKET BY PRODUCT TYPE
- 28.1.3 APAC MARKET BY PRODUCT TYPE
- 28.1.4 LATIN AMERICA MARKET BY PRODUCT TYPE
- 28.1.5 MIDDLE EAST & AFRICA MARKET BY PRODUCT TYPE
28.2 MARKET BY APPLICATION
- 28.2.1 NORTH AMERICA MARKET BY APPLICATION
- 28.2.2 EUROPE MARKET BY APPLICATION
- 28.2.3 APAC MARKET BY APPLICATION
- 28.2.4 LATIN AMERICA MARKET BY APPLICATION
- 28.2.5 MIDDLE EAST & AFRICA MARKET BY APPLICATION
28.3 MARKET BY END-USER
- 28.3.1 NORTH AMERICA MARKET BY END-USER
- 28.3.2 EUROPE MARKET BY END-USER
- 28.3.3 APAC MARKET BY END-USER
- 28.3.4 LATIN AMERICA MARKET BY END-USER
- 28.3.5 MIDDLE EAST & AFRICA MARKET BY END-USER
28.4 MARKET BY METHOD
28.5 MARKET BY WORKFLOW
28.6 MARKET BY GEOGRAPHY
- 28.6.1 SINGLE-USE BIOPROCESSING EQUIPMENT MARKET BY GEOGRAPHY
- 28.6.2 SIMPLE & PERIPHERAL DEVICES MARKET BY GEOGRAPHY
- 28.6.3 MONOCLONAL ANTIBODIES (MABS) MARKET BY GEOGRAPHY
- 28.6.4 VACCINES MARKET BY GEOGRAPHY
- 28.6.5 CELL THERAPIES MARKET BY GEOGRAPHY
- 28.6.6 OTHERS MARKET BY GEOGRAPHY
- 28.6.7 BIOPHARMACEUTICAL MANUFACTURERS MARKET BY GEOGRAPHY
- 28.6.8 CONTRACT MANUFACTURING ORGANIZATIONS (CMOS) MARKET BY GEOGRAPHY
- 28.6.9 R&D COMPANIES AND RESEARCH INSTITUTES MARKET BY GEOGRAPHY

29 APPENDIX

29.1 ABBREVIATIONS